[go: up one dir, main page]

NO20080284L - Cannabionoid aktiv farmasoytisk ingrediens for forbedrede doseringsformer - Google Patents

Cannabionoid aktiv farmasoytisk ingrediens for forbedrede doseringsformer

Info

Publication number
NO20080284L
NO20080284L NO20080284A NO20080284A NO20080284L NO 20080284 L NO20080284 L NO 20080284L NO 20080284 A NO20080284 A NO 20080284A NO 20080284 A NO20080284 A NO 20080284A NO 20080284 L NO20080284 L NO 20080284L
Authority
NO
Norway
Prior art keywords
active pharmaceutical
cannabionoid
dosage forms
pharmaceutical ingredient
improved dosage
Prior art date
Application number
NO20080284A
Other languages
English (en)
Inventor
Robert J Kupper
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36922253&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20080284(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of NO20080284L publication Critical patent/NO20080284L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01B—CABLES; CONDUCTORS; INSULATORS; SELECTION OF MATERIALS FOR THEIR CONDUCTIVE, INSULATING OR DIELECTRIC PROPERTIES
    • H01B3/00—Insulators or insulating bodies characterised by the insulating materials; Selection of materials for their insulating or dielectric properties
    • H01B3/02—Insulators or insulating bodies characterised by the insulating materials; Selection of materials for their insulating or dielectric properties mainly consisting of inorganic substances
    • H01B3/10—Insulators or insulating bodies characterised by the insulating materials; Selection of materials for their insulating or dielectric properties mainly consisting of inorganic substances metallic oxides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nanotechnology (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)

Abstract

Farmasøytiske sammensetninger som innbefatter kannabinoidaktive, farmasøytiske ingredienser, krystallinsk trans-(±)-?9-tetrahydrokannabinol og formuleringer derav er beskrevet. Oppfinnelsen angår også fremgangsmåter for behandling eller hindring av en tilstand slik som smerte som innbefatter administrering til en pasient som trenger det, en effektiv mengde av krystallinsk trans-(±)- ?9-tetrahydrokannabinol. I spesifikke utførelsesformer kan den krystallinske trans-(±)- ?9-tetrahydrokannabinolen administreres i henhold til fremgangsmåter for behandling eller hindring av en tilstand slik som smerte ha en renhet på minst ca. 98% basert på totalvekten på kannabinoidene.
NO20080284A 2005-06-16 2008-01-15 Cannabionoid aktiv farmasoytisk ingrediens for forbedrede doseringsformer NO20080284L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69136105P 2005-06-16 2005-06-16
US72650905P 2005-10-12 2005-10-12
PCT/EP2006/005761 WO2006133941A2 (en) 2005-06-16 2006-06-14 Cannabinoid active pharmaceutical ingredient for improved dosage forms

Publications (1)

Publication Number Publication Date
NO20080284L true NO20080284L (no) 2008-03-07

Family

ID=36922253

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080284A NO20080284L (no) 2005-06-16 2008-01-15 Cannabionoid aktiv farmasoytisk ingrediens for forbedrede doseringsformer

Country Status (30)

Country Link
US (1) US20070072939A1 (no)
EP (3) EP2263667A3 (no)
JP (2) JP2008543800A (no)
KR (3) KR20080026176A (no)
AP (1) AP2405A (no)
AR (1) AR054064A1 (no)
AT (1) ATE489085T1 (no)
AU (1) AU2006257059C1 (no)
BR (1) BRPI0612922A2 (no)
CA (1) CA2612061A1 (no)
CR (2) CR9662A (no)
CY (1) CY1111446T1 (no)
DE (1) DE602006018466D1 (no)
DK (1) DK1901734T3 (no)
EA (1) EA016813B1 (no)
EC (1) ECSP078023A (no)
HR (1) HRP20110129T1 (no)
IL (1) IL188150A0 (no)
MA (1) MA29630B1 (no)
MX (1) MX2007016051A (no)
MY (1) MY140576A (no)
NO (1) NO20080284L (no)
NZ (2) NZ563049A (no)
PL (1) PL1901734T3 (no)
PT (1) PT1901734E (no)
RS (1) RS51569B (no)
SI (1) SI1901734T1 (no)
TN (1) TNSN07478A1 (no)
TW (1) TWI366460B (no)
WO (1) WO2006133941A2 (no)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
TWI369203B (en) 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
CN101132781A (zh) * 2004-12-09 2008-02-27 茵西斯医疗公司 在室温下稳定的屈大麻酚剂型
KR100753959B1 (ko) * 2006-01-12 2007-08-31 에이펫(주) 기판 건조장치를 이용한 기판 건조방법
WO2008006226A1 (en) * 2006-07-14 2008-01-17 Wine, Harvey Transdermal formulations of synthetic cannabinoids and nano colloidal silica
US20080069871A1 (en) * 2006-07-21 2008-03-20 Vaughn Jason M Hydrophobic abuse deterrent delivery system
WO2008019146A2 (en) * 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
US8039509B2 (en) * 2006-11-10 2011-10-18 Johnson Matthey Public Limited Company Composition comprising (−)-Δ9-trans-tetrahydrocannabinol
US8980940B2 (en) 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
JP2010535238A (ja) 2007-07-30 2010-11-18 オールトランツ インコーポレイティド カンナビジオールのプロドラッグ、カンナビジオールのプロドラッグを含む組成物及びその使用方法
JP2010535774A (ja) * 2007-08-06 2010-11-25 インシス セラピューティクス インコーポレイテッド 経口カンナビノイド液体製剤および治療方法
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
DK2230934T3 (da) 2007-12-14 2012-11-26 Aerodesigns Inc Afgivelse af aerosoliserbare næringsmiddelprodukter
GB0807915D0 (en) * 2008-05-01 2008-06-04 Resolution Chemicals Ltd Production of delta 9 tetrahydrocannabinol
CA2766482C (en) * 2009-06-29 2017-10-24 Bender Analytical Holding B.V. Drug delivery system comprising polyoxazoline and a bioactive agent
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
ES2408343B2 (es) 2010-05-10 2014-07-17 Euro-Celtique, Sa Composiciones farmacéuticas que comprenden hidromorfona y naloxona
MX344846B (es) 2010-05-10 2017-01-10 Euro-Celtique S A * Combinacion de granulos cargados activos con activos adicionales.
US9993433B2 (en) 2010-05-10 2018-06-12 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
US8703727B2 (en) * 2010-08-24 2014-04-22 Aphios Corporation Nanotechnology formulation of poorly soluble compounds
US8629177B2 (en) * 2010-08-24 2014-01-14 Aphios Corporation Nanoencapsulated delta-9-tetrahydrocannabinol
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
AU2011366911B2 (en) 2011-04-28 2016-03-24 Acme Specialty Products, Llc Taste masking compositions and edible forms thereof
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US10350251B2 (en) * 2012-03-28 2019-07-16 Keith Gerald Freeman Medical compositions, methods of making and using those compositions, and kits including those compositions
WO2013179264A2 (en) * 2012-05-30 2013-12-05 Universidad Andres Bello Use of compounds that selectively modulate astrocytic release of substances through hemichannels of connexins and pannexins, without influencing gap junctions, for the treatment of psychiatric disorders
US11253472B2 (en) 2012-10-04 2022-02-22 Benuvia Therapeutics Llc Oral cannabinoid formulations
US12496271B2 (en) 2019-02-22 2025-12-16 Benuvia Operations, Llc Oral cannabinoid formulations
US9345771B2 (en) 2012-10-04 2016-05-24 Insys Development Company, Inc. Oral cannabinoid formulations
US10265293B2 (en) 2012-10-04 2019-04-23 Insys Development Company, Inc. Oral cannabinoid formulations
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CA2900982C (en) 2013-02-12 2021-06-01 Corbus Pharmaceuticals Inc. Ultrapure tetrahydrocannabinol-11-oic acids
US10149823B2 (en) 2013-04-30 2018-12-11 Otitopic Inc. Dry powder formulations and methods of use
US9616025B2 (en) 2013-10-29 2017-04-11 Echo Pharmaceuticals B.V. Compressed tablet containing Δ9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment
ES2610988T3 (es) 2013-10-29 2017-05-04 Echo Pharmaceuticals B.V. Comprimido que contiene cannabidiol, método para su producción y uso de tal comprimido en el tratamiento oral de trastornos psicóticos o de ansiedad
EP3068397A1 (en) 2013-11-13 2016-09-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
DK3094318T3 (da) * 2014-01-13 2020-05-04 Kannalife Sciences Inc Ny funktionaliseret 1,3-benzendioler og deres anven-delsesmetode til behandling af hepatisk encephalopati
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
US10610512B2 (en) 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use
CN107075523B (zh) * 2014-06-27 2022-04-19 加拿大国家研究委员会 来自大麻的大麻环萜酚酸合酶
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
US20160143972A1 (en) * 2014-11-21 2016-05-26 Cannamark Inc. Method and apparatus for preparing a solid form of cannabinoid
EP3268043A4 (en) 2015-03-10 2018-12-19 Nanosphere Health Sciences, LLC Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
AU2016326626A1 (en) * 2015-09-24 2018-04-26 Pasenture, Inc. Cannabinoid compositions and methods of making
US10555906B2 (en) * 2016-02-11 2020-02-11 Gelpell Ag Oral solid cannabinoid formulations, methods for producing and using thereof
US10542770B2 (en) 2016-03-18 2020-01-28 Aceso Wellness LLC Cannabinoid emulsion product and process for making the same
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US10588974B2 (en) 2016-04-22 2020-03-17 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
EP3472307A4 (en) * 2016-06-15 2020-03-25 Ojai Energetics PBC Methods and compositions for potentiating stem cell therapies
PT3474844T (pt) 2016-06-28 2022-11-08 Trichomeshell Ltd Uma forma de dosagem para ser vaporizada e fumada
US9717683B1 (en) 2016-06-29 2017-08-01 Ep Pharma, Llc Low-temperature inhalation administration of cannabinoid entities
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
EA201892396A1 (ru) * 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
US20190224117A1 (en) * 2017-06-14 2019-07-25 Yury Leon Shmerlis Cannabis Extract Chewing Gum
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
EP3665145A1 (en) 2017-08-07 2020-06-17 Enantia, S.L. A cocrystal of 2-[(1r,6r)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
CN117752606A (zh) * 2017-08-27 2024-03-26 罗得技术公司 用于治疗眼科病症的药物组合物
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CN115919780A (zh) 2017-09-22 2023-04-07 维克图拉公司 含有硬脂酸镁的干粉组合物
US10220061B1 (en) 2017-09-26 2019-03-05 Cynthia Denapoli Method of reducing stress and anxiety in equines
HRP20220277T1 (hr) 2017-09-28 2022-05-13 Zynerba Pharmaceuticals, Inc. Liječenje fragilnog x sindroma i autizma kanabidiolom
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US11179340B2 (en) * 2017-12-29 2021-11-23 TGC Network LLC Cannabidiol dosage form
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
CA3108216A1 (en) * 2018-07-18 2020-01-23 Glatt Gmbh Immediate release formulations of cannabinoids
EP3833369A4 (en) 2018-08-08 2022-05-04 Neptune Wellness Solutions Inc. PROCESS FOR COLD EXTRACTION OF CANNABINOIDS AND TERPENES FROM CANNABIS BY ORGANIC SOLVENTS
PE20211198A1 (es) * 2018-10-10 2021-07-01 Tilray Inc Metodos y formulaciones para tratar nauseas y vomitos inducidos por quimioterapia
EP3864000A4 (en) 2018-10-10 2022-08-10 Treehouse Biosciences, Inc. CANNABIGEROL SYNTHESIS
EP3873459A1 (en) 2018-10-31 2021-09-08 Enantia, S.L. Solid compositions of cocrystals of cannabinoids
AR117118A1 (es) 2018-11-19 2021-07-14 Receptor Holdings Inc Aminoácidos grasos n-acilados para reducir la variabilidad de absorción en composiciones a base de cannabinoides
WO2020123407A1 (en) 2018-12-11 2020-06-18 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
KR20210104084A (ko) 2018-12-14 2021-08-24 지네르바 파마슈티컬스, 인코포레이티드 칸나비디올을 사용하는 22q11.2 결실 증후군의 치료
US10959961B2 (en) 2018-12-14 2021-03-30 Natural Extraction Systems, LLC Methods of administering anionic cannabinoid molecules dissolved in water
AU2019397508A1 (en) * 2018-12-14 2021-06-24 Natural Extraction Systems, LLC Compositions and methods related to anionic cannabinoid molecules
US10609944B1 (en) 2018-12-14 2020-04-07 Natural Extraction Systems, LLC Compositions comprising 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-3-hydroxy-5-pentylphenolate and 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
WO2020176526A1 (en) * 2019-02-25 2020-09-03 Paul Mendell Methods for delivering nutritional and therapeutic supplements with food and drug products
CN112062697B (zh) * 2019-05-22 2023-09-01 上海特化医药科技有限公司 间苯多酚衍生物及其制备方法
IL288196B2 (en) * 2019-05-23 2025-08-01 Kare Chemical Tech Inc Catalytic cannabinoid processes and precursors
WO2020264199A1 (en) * 2019-06-26 2020-12-30 Natural Extraction Systems, LLC Containers, compositions, methods related to cannabinoid anions
EP4041208A4 (en) * 2019-09-18 2023-07-19 Board of Regents, The University of Texas System Compositions of cannabinoids for delivery by inhalation
US11542243B1 (en) 2019-09-26 2023-01-03 FusionFarms, LLC Method of converting delta9-THC to delta10-THC and the purification of the delta10-THC by crystallization
EP4037663A1 (en) 2019-10-03 2022-08-10 Starton Therapeutics, Inc. Transdermal delivery of dronabinol
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
WO2021071967A1 (en) * 2019-10-09 2021-04-15 Island Breeze Systems Ca, Llc Compositions for pulmonary delivery of cannabinoids and associated methods and systems
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
AU2020361741B2 (en) 2019-10-11 2024-09-05 Pike Therapeutics Inc. Transdermal compositions comprising cannabidiol (CBD) for use in the treatment of seizure disorders
WO2021072325A1 (en) * 2019-10-11 2021-04-15 Corbus Pharmaceuticals, Inc. Compositions of ajulemic acid and uses thereof
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
WO2021074790A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
KR20240134147A (ko) * 2019-10-21 2024-09-06 이솔레이트 엘티디 초미세 화합물 및 이의 제조
GB2588456B (en) * 2019-10-25 2023-02-01 Gw Res Ltd Cannabinoid compound
GB2588457B (en) * 2019-10-25 2022-12-21 Gw Res Ltd Cannabinoid compound
GB2588455B (en) * 2019-10-25 2022-12-21 Gw Res Ltd Cannabinoid compound
WO2021096886A1 (en) * 2019-11-11 2021-05-20 Natural Extraction Systems, LLC Methods to separate cannabinoids from impurities by crystallization
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
WO2021195540A1 (en) * 2020-03-26 2021-09-30 Radient Technologies Innovations Inc. Cannabinoid based composition for mitigation of viral effects
AU2021276680A1 (en) 2020-05-22 2023-01-19 Ilera Derm LLC Compositions for treating acne and dermatological conditions
US12349706B2 (en) 2020-07-31 2025-07-08 Natural Extraction Systems, LLC Compositions and methods related to excipients and cannabinoid formulations
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
IL278286B (en) 2020-10-25 2021-06-30 Fine Can Ltd Cannabis powders and their uses
WO2022115718A1 (en) * 2020-11-29 2022-06-02 Castor Trevor P Extraction, separation and purification of cannabinoids from cannabis staiva and other marijuana biomass
US20220317097A1 (en) * 2021-04-05 2022-10-06 Grant Kraus Atmospheric Triphasic Chromatography (ATC) method
WO2022232574A1 (en) 2021-04-29 2022-11-03 Tilray, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
US20220387256A1 (en) * 2021-06-03 2022-12-08 Kent Byron Vial With Metered Dispenser
WO2023015102A1 (en) * 2021-07-26 2023-02-09 Rapid Therapeutic Sciences Laboratories, Inc. Process for producing cbd isolate
PL4124336T3 (pl) 2021-07-30 2024-02-26 Cannamedical Pharma Gmbh Plaster przezśluzówkowy obejmujący kannabinoid i/lub opioid
CN115784836A (zh) * 2022-12-08 2023-03-14 南京康立瑞生物科技有限公司 一种高选择性的制备反式-薄荷基-2,8-二烯-1-醇的方法
WO2024160792A1 (en) 2023-01-30 2024-08-08 Cannamedical Pharma Gmbh Improved transmucosal patch comprising a cannabinoid and/or an opioid
KR20240172412A (ko) * 2023-06-01 2024-12-10 제주대학교 산학협력단 올리베톨 또는 이의 약제학적으로 허용가능한 염을 유효성분으로 포함하는, 뇌전증 또는 퇴행성 신경질환의 예방 및 치료용 약학 조성물
WO2025164161A1 (ja) * 2024-01-29 2025-08-07 シオノギファーマ株式会社 カンナビジオールの溶媒和物及びカンナビジオールの精製方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2744938A (en) * 1952-07-24 1956-05-08 Universal Oil Prod Co Removal of color impurities from organic compounds
US3507885A (en) 1966-03-25 1970-04-21 Hoffmann La Roche 3-alkyl-6h-dibenzo(b,d)pyrans
CH481911A (de) 1967-05-19 1969-11-30 Theodor Dr Petrzilka Verfahren zur Herstellung von tricyclischen Verbindungen
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3668224A (en) * 1970-07-02 1972-06-06 Theodor Petrzilka PROCESS OF PRODUCING 6a, 10a-TRANS-6a,7,8,10a-TETRAHYDRODIBENZO (b,d)-PYRANS
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4316893A (en) 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4025516A (en) 1975-06-23 1977-05-24 The John C. Sheehan Institute For Research, Inc. Process for the preparation of (-)-6a,10a-trans-6a,7,8,10a-tetrahydrodibenzo[b,d]-pyrans
US4381399A (en) 1981-12-21 1983-04-26 Aerojet-General Corporation Purification of tetrahydrodibenzo[b,d]pyrans from crude synthetic mixtures
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
DE4100441A1 (de) 1991-01-09 1992-07-16 Mack Chem Pharm Verfahren zur herstellung von 6,12-dihydro-6-hydroxy-cannabidiol und dessen verwendung zur herstellung von trans-delta-9-tetrahydrocannabinol
US6703418B2 (en) * 1991-02-26 2004-03-09 Unimed Pharmaceuticals, Inc. Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
US5338753A (en) 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
US5389375A (en) * 1993-05-21 1995-02-14 University Of Mississippi Stable suppository formulations effecting bioavailability of Δ9 -thc
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
JPH11507670A (ja) 1995-06-12 1999-07-06 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ−２インヒビターと５−リポキシゲナーゼインヒビターの組合せによる炎症と炎症関連疾患の治療
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US6328992B1 (en) 1997-03-03 2001-12-11 Lawrence L. Brooke Cannabinoid patch and method for cannabis transdermal delivery
US6132762A (en) 1997-05-05 2000-10-17 Cristobal; Walter Transcutaneous application of marijuana
US5932557A (en) 1997-08-12 1999-08-03 Mustafa; S. Jamal Adenosine A1 receptor antisense oligonucleotide treatment of alcohol and marijuana-induced psychomotor impairments
US6162829A (en) 1997-10-17 2000-12-19 Atlantic Pharmaceuticals, Inc. (3R,4R)-Δ8 -tetrahydrocannabinol-11-oic acids useful as antiinflammatory agents and analgesics
GB9726916D0 (en) 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
CA2340445A1 (en) 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
US6365416B1 (en) 1998-10-26 2002-04-02 The University Of Mississippi Method of preparing delta-9-tetrahydrocannabinol
US6509005B1 (en) 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
TW507028B (en) * 1999-02-12 2002-10-21 Asahi Chemical Ind A moisture-absorbable synthetic fiber with an improved moisture-release property
FI990915A0 (fi) 1999-04-23 1999-04-23 Orion Yhtymae Oyj Jauheinhalaattori
US6403126B1 (en) * 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6747058B1 (en) 1999-08-20 2004-06-08 Unimed Pharmaceuticals, Inc. Stable composition for inhalation therapy comprising delta-9-tetrahydrocannabinol and semiaqueous solvent therefor
MXPA02005103A (es) 1999-10-18 2003-09-25 Alexipharma Inc Ligandos selectivos del receptor de canabinoide (cb2) perifericos.
US6943266B1 (en) 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US6900236B1 (en) 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
IL132661A (en) 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for peripheral cannabinoid receptors
HK1052183A1 (zh) * 2000-03-10 2003-09-05 Pharmacia Corporation 制造tetrahydrobenzothiepines的方法
US6620351B2 (en) 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
GB2368061B (en) 2000-10-20 2005-05-11 Gw Pharmaceuticals Ltd Dose dispensing apparatus
MXPA03003895A (es) 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
US6730330B2 (en) 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
CH695661A5 (de) 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
WO2002070506A2 (en) * 2001-03-07 2002-09-12 Websar Innovations Inc. Conversion of cbd to δ8-thc and δ9-thc
US20030050334A1 (en) * 2001-04-30 2003-03-13 Murty Ram B. Process for extraction of Delta-9-Tetrahydrocannabinol and other related cannabinoids and preparation of specific strength marijuana cigarettes
GB0112752D0 (en) 2001-05-25 2001-07-18 Johnson Matthey Plc Synthesis of cannabinoids
WO2003064407A2 (en) * 2002-02-01 2003-08-07 Resolution Chemicals Limited Production of δ9 tetrahydrocannabinol
WO2003070506A1 (fr) 2002-02-21 2003-08-28 Biel Timothee Dispositif d'entraînement pour vehicules a moteur, notamment avec propulsion hybride
ES2342660T3 (es) * 2002-02-26 2010-07-12 Astrazeneca Ab Nuevas formas cristalinas del compuesto anticancerigeno zd1839.
UA79281C2 (en) * 2002-04-03 2007-06-11 Solvay Pharm Bv Stabilized composition comprising a natural cannabinoid compound and process for the preparation thereof
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
DE60326354D1 (de) 2002-08-20 2009-04-09 Euro Celtique Sa Transdermale dosierungsform enthaltend einen wirkstoff und einen antagonisten in freier base und in salz form
US20040229939A1 (en) 2003-02-14 2004-11-18 Chowdhury Dipak K. Tetrahydrocannabinol compositions and methods of manufacture and use thereof
TW589663B (en) 2003-05-12 2004-06-01 Au Optronics Corp Flat panel display and manufacturing method thereof
WO2005044093A2 (en) * 2003-11-05 2005-05-19 Unimed Pharmaceuticals, Inc. Delta-9- the treatment of multiple sclerosis
GB0329635D0 (en) * 2003-12-23 2004-01-28 Johnson Matthey Plc Process for purifying trans-tetrahydrocannabinol
CN1997636B (zh) * 2004-07-19 2011-09-28 希莱格有限公司 获得纯四氢大麻酚的方法
SE0402485D0 (sv) * 2004-10-13 2004-10-13 Astrazeneca Ab Polymorph of N,N-Diethyl-4-(3-Fluorophenyl-Piperidin-4-Ylidene-Methyl)-Benzamide Hydrochloride salt
GB0425445D0 (en) * 2004-11-18 2004-12-22 Smithkline Beecham Corp Novel compositions
TWI369203B (en) * 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol

Also Published As

Publication number Publication date
AU2006257059C1 (en) 2010-02-04
TNSN07478A1 (fr) 2009-03-17
CY1111446T1 (el) 2015-08-05
NZ563049A (en) 2010-09-30
PT1901734E (pt) 2011-03-02
DE602006018466D1 (de) 2011-01-05
TW200718418A (en) 2007-05-16
BRPI0612922A2 (pt) 2010-12-07
CR9662A (es) 2008-03-07
AR054064A1 (es) 2007-05-30
WO2006133941A2 (en) 2006-12-21
AP2007004247A0 (en) 2007-12-31
EP2279735A2 (en) 2011-02-02
EP2263667A3 (en) 2011-04-06
HRP20110129T1 (hr) 2011-03-31
US20070072939A1 (en) 2007-03-29
SI1901734T1 (sl) 2011-02-28
KR20080026176A (ko) 2008-03-24
PL1901734T3 (pl) 2011-05-31
JP2008543800A (ja) 2008-12-04
AP2405A (en) 2012-05-02
TWI366460B (en) 2012-06-21
HK1118447A1 (en) 2009-02-13
JP2012211172A (ja) 2012-11-01
EP2279735A3 (en) 2011-03-16
DK1901734T3 (da) 2011-02-21
EP1901734B1 (en) 2010-11-24
EA200800056A1 (ru) 2008-06-30
AU2006257059B2 (en) 2009-06-11
EA016813B1 (ru) 2012-07-30
NZ598030A (en) 2013-05-31
ATE489085T1 (de) 2010-12-15
MY140576A (en) 2009-12-31
RS51569B (sr) 2011-08-31
MA29630B1 (fr) 2008-07-01
CA2612061A1 (en) 2006-12-21
WO2006133941A3 (en) 2007-03-15
MX2007016051A (es) 2008-03-10
KR20130067323A (ko) 2013-06-21
CR20130263A (es) 2013-07-09
KR20100102237A (ko) 2010-09-20
EP1901734A2 (en) 2008-03-26
ECSP078023A (es) 2008-01-23
IL188150A0 (en) 2008-03-20
EP2263667A2 (en) 2010-12-22
AU2006257059A1 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
NO20080284L (no) Cannabionoid aktiv farmasoytisk ingrediens for forbedrede doseringsformer
SA521421897B1 (ar) تركيبة تعتمد على جزء من نباتات طبية أو مستخلصاتها واستخداماتها ومنتجاتها
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
MY143795A (en) Tetrahydropyridoindole derivatives
EP1587506A4 (en) ADMINISTRATION OF CAPSAICINOIDS
NO20073059L (no) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
MX344787B (es) Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara.
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
HUP0104718A2 (hu) Mikronizált eplerenon kompozíciók és eljárás az előállításukra
NO20081731L (no) Trazodon-sammensetning for en gang om dagen administrering
PT1207756E (pt) Utilizacao de espinosade ou de uma formulacao que compreende espinosade
PL373276A1 (en) Trans-epicutaneous administration form for treating restless leg syndrome
EP1852114A4 (en) COMPOSITION WITH DIHOMO (GAMMA) LINE ACIDIC ACID (DGLA) AS AN ACTIVE INGREDIENTS
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
NO20092763L (no) Isosorbid mononitrat derivater for behandling av tarmlidelser
EP2050442A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF BONE DISORDERS, FUNCTIONAL FOOD OR HEALTH MEASURES CONTAINING THIS COMPOSITION AND PHARMACEUTICAL PREPARATION CONTAINING THE COMPOSITION AS AN ACTIVE SUBSTANCE
UA92498C2 (ru) Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
NO20073575L (no) Farmasoytiske sammensetninger for behandling av cellulitt
NO20090067L (no) Farmasoytiske kombinasjoner for behandling av respiratoriske sykdommer
NO20061236L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og paratyroidhoziiton
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
Alqurashi et al. Protective effect of sterubin against neurochemical and behavioral impairments in rotenone-induced Parkinson's disease
DK1893237T3 (da) Farmaceutisk sammensætning, der omfatter en organopolysiloxan ela-stomer og et solubiliseret aktivt stof
MX2022011961A (es) Composición que tiene aceptación voluntaria mejorada.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: EURO-CELTIQUE SA, LU

FC2A Withdrawal, rejection or dismissal of laid open patent application